RAHUL BHARGAVA

Emicizumab brings hope to Haemophilia A patients, accessibility remains a challenge

According to experts, Emicizumab prophylaxis is considered to be a far superior and effective way of managing Haemophilia A in comparison to other traditional treatment options. Current treatment options of ODT like Factor VIII replacement, FVIII concentrates and bypass agents that prevail in the market are sub-optimal inadequate.

• Exclusive